Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Phase of Trial: Phase II/III
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms GANCIMVEAR
- 01 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
- 01 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jun 2019.
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.